WO2003066095A3 - MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING - Google Patents

MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING Download PDF

Info

Publication number
WO2003066095A3
WO2003066095A3 PCT/NL2003/000087 NL0300087W WO03066095A3 WO 2003066095 A3 WO2003066095 A3 WO 2003066095A3 NL 0300087 W NL0300087 W NL 0300087W WO 03066095 A3 WO03066095 A3 WO 03066095A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
tolerance
fcϝriib
receptor signalling
antigen
Prior art date
Application number
PCT/NL2003/000087
Other languages
French (fr)
Other versions
WO2003066095A2 (en
Inventor
Janneke Nicoline Samsom
Reina Elizabeth Mebius
Helvoort Johannes Martinus Van
George Kraal
Original Assignee
Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Janneke Nicoline Samsom
Reina Elizabeth Mebius
Helvoort Johannes Martinus Van
George Kraal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP02075521 priority Critical
Priority to EP02075521.1 priority
Application filed by Vereniging Voor Christelijk Wetenschappelijk Onderwijs, Janneke Nicoline Samsom, Reina Elizabeth Mebius, Helvoort Johannes Martinus Van, George Kraal filed Critical Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Publication of WO2003066095A2 publication Critical patent/WO2003066095A2/en
Publication of WO2003066095A3 publication Critical patent/WO2003066095A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Abstract

The invention relates to the field of immunology and medicine. It particularly relates to a method for modulating tolerance to an antigen involved in an allergic reaction or in an autoimmune disorder or an antigen used in a vaccine. The invention provides a method for modulating tolerance to an antigen involved in an allergic reaction or in an autoimmune disorder or an antigen used in a vaccine comprising providing a ligand capable of modulating FcϜRIIB receptor signalling.
PCT/NL2003/000087 2002-02-07 2003-02-07 MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING WO2003066095A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02075521 2002-02-07
EP02075521.1 2002-02-07

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003206264A AU2003206264A1 (en) 2002-02-07 2003-02-07 MODULATING TOLERANCE BY MODULATING FcGammaRIIB RECEPTOR SIGNALLING

Publications (2)

Publication Number Publication Date
WO2003066095A2 WO2003066095A2 (en) 2003-08-14
WO2003066095A3 true WO2003066095A3 (en) 2003-12-31

Family

ID=27675702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2003/000087 WO2003066095A2 (en) 2002-02-07 2003-02-07 MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING

Country Status (2)

Country Link
AU (1) AU2003206264A1 (en)
WO (1) WO2003066095A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8951517B2 (en) 2003-01-09 2015-02-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9243069B2 (en) 2008-04-02 2016-01-26 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using the same
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016750A2 (en) * 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP1761563A4 (en) 2004-05-10 2008-05-14 Macrogenics Inc HUMANIZED Fc gamma RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP2029173B1 (en) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032734A1 (en) * 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032734A1 (en) * 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
OTT VANESSA L ET AL: "FcgammaRIIB as a potential molecular target for intravenous gamma globulin therapy.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 108, no. 4 Supplement, October 2001 (2001-10-01), pages S95 - S98, XP008008611, ISSN: 0091-6749 *
RAVETCH JEFFREY V ET AL: "IgF Fc receptors.", ANNUAL REVIEW OF IMMUNOLOGY, vol. 19, 2001, 2001 Annual Reviews 4139 El Camino Way, Palo Alto, CA, 94303-0139, USA, pages 275 - 290, XP008008612, ISBN: 0-8243-3019-6 *
RAVETCH JEFFREY V: "Fc receptors: Activation-inhibition receptor pairing.", ACTIVATING AND INHIBITORY IMMUNOGLOBULIN-LIKE RECEPTORS., 2001, CREST International Symposium on Immunoglobulin-like Receptors;Sendai City, Japan; September 18-19, 2000, Springer-Verlag Tokyo Inc.;Springer-Verlag New York Inc. 3-13 Hongo 3-chome, Bunkyo-ku, Tokyo,, pages 1 - 4, XP008008610, ISBN: 4-431-70297-0 *
SAMUELSSON ASTRID ET AL: "Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.", SCIENCE (WASHINGTON D C), vol. 291, no. 5503, 2001, pages 484 - 486, XP002215958, ISSN: 0036-8075 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8951517B2 (en) 2003-01-09 2015-02-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9243069B2 (en) 2008-04-02 2016-01-26 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using the same
US9469692B2 (en) 2008-04-02 2016-10-18 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Also Published As

Publication number Publication date
WO2003066095A2 (en) 2003-08-14
AU2003206264A1 (en) 2003-09-02
AU2003206264A8 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
AU2005232562B2 (en) Flange occlusion devices and methods
TWI342502B (en) System facilitating displaying objects,computer employing the same,computer readable medium having stored thereon the computer executable components thereof,method and system facilitating accessing objects,computer readable medium having stored thereon t
EP2664550B8 (en) Safety Drug Handling Device
GB2423846B (en) Haptic information presentation system and method
CA2519089C (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
DK1578397T3 (en) Human monoclonal antibodies against CD25
IL175915D0 (en) Substituted imidazo ring systems and methods
AU2002338454A1 (en) Permission based marketing for use with medical prescriptions
EP1572941A4 (en) Novel flavivirus antigens
TWI322693B (en) Pharmaceutical preparation comprising an antibody against the egf receptor
AU2003258155A8 (en) Method and system for integrating enterprise software applications with desktop software applications
HK1084958A1 (en) S. pneumoniae antigens
NO20071188L (en) Humanized anti-cMet antagonists
AU2003267276A8 (en) Systems and methods for providing insurance and non-insurance products
DE60303292D1 (en) Delivery device for drugs and methods for the delivery of drugs
EP1730489A4 (en) Crystal forming devices and systems and methods for making and using the same
AU2003246698A1 (en) Disubstituted pyrazolyl carboxanilides
WO2004058179A3 (en) Immunostimulatory sequence oligonucleotides and methods of using the same
AU2003223728A1 (en) Methods and systems for acquiring seismic data
AU2002329174A1 (en) Gastric treatment and diagnosis device and method
WO2004056312A3 (en) Immunoglobulin variants and uses thereof
AU2003298730A1 (en) An electronic clinical reference and education system and method of use
EP1363225A3 (en) Systems and methods for a consumer to determine food/medicine interactions
SI2603530T1 (en) Anti-fap antibodies and methods of use
NL1023710A1 (en) Method and device for the production of calibration data for a digital camera.

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
WWW Wipo information: withdrawn in national office

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: JP